false 0001178879 0001178879 2024-06-06 2024-06-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT TO

SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): June 6, 2024

 

AMICUS THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware   001-33497   71-0869350
(State or Other Jurisdiction
of Incorporation)		   (Commission
File Number)		   (I.R.S. Employer
Identification No.)

 

47 Hulfish Street, Princeton, New Jersey 08542

(Address of Principal Executive Offices, and Zip Code)

 

609-662-2000

Registrant’s Telephone Number, Including Area Code

 

(Former Name or Former Address, if Changed Since Last Report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock Par Value $0.01   FOLD   Nasdaq

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company  ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 
 

 

Item 5.07 - Submission of Matters to a Vote of Security Holders.

 

At the 2024 Annual Meeting of Stockholders of the Company, held on June 6, 2024, the Company’s stockholders elected Eiry W. Roberts, Craig A. Wheeler and Burke W. Whitman as Class II directors to serve a three-year term expiring at the 2027 Annual Meeting of Stockholders and until their respective successors have been elected. In addition, the stockholders (i) approved the Amended and Restated 2007 Equity Incentive Plan, (ii) ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024, and (iii) approved, on an advisory basis, the compensation paid to the Company’s named executive officers. The final voting results on these matters were as follows:

 

  1. Election of Directors.

 

Nominee  Votes For   Votes Withheld   Broker Non-Votes 
Eiry W. Roberts   248,107,021    6,738,791    11,256,697 
Craig A. Wheeler   248,172,753    6,673,059    11,256,697 
Burke W. Whitman   245,493,258    9,352,554    11,256,697 

 

  2. Approval of the Amended and Restated 2007 Equity Incentive Plan.

 

Votes For   Votes Against   Votes Abstain   Broker Non-Votes 
 245,475,071    9,101,663    269,078    11,256,697 

 

  3. Ratification of Ernst & Young LLC as the Company's Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2023.

 

Votes For   Votes Against   Votes Abstain   Broker Non-Votes 
 258,841,833    7,207,672    53,004    - 

 

  4. Approval, on an advisory basis, of the Company's executive compensation.

 

Votes For   Votes Against   Votes Abstain   Broker Non-Votes 
 246,376,429    6,826,611    1,642,772    11,256,697 

 

 

 

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits:

 

Exhibit No.   Description
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

Signature Page

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  AMICUS THERAPEUTICS, INC.
   
Date: June 7, 2024 By: /s/ Ellen S. Rosenberg
  Name: Ellen S. Rosenberg
  Title: Chief Legal Officer and Corporate Secretary

 

 

 

v3.24.1.1.u2
Cover
Jun. 06, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 06, 2024
Entity File Number 001-33497
Entity Registrant Name AMICUS THERAPEUTICS, INC.
Entity Central Index Key 0001178879
Entity Tax Identification Number 71-0869350
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 47 Hulfish Street
Entity Address, City or Town Princeton
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08542
City Area Code 609
Local Phone Number 662-2000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock Par Value $0.01
Trading Symbol FOLD
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Amicus Therapeutics (NASDAQ:FOLD)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Amicus Therapeutics Charts.
Amicus Therapeutics (NASDAQ:FOLD)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Amicus Therapeutics Charts.